Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · 20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs says Q2 2026 cancer testing revenue rose 47% year over year

Positive Impact 3 of 5 other Written later

In an investor webinar presentation furnished under Regulation FD, 20/20 Biolabs said Q2 2026 was its best quarter to date for cancer testing revenue, up 47% year over year. The presentation also described two preliminary, non-binding discussions with senior FDA personnel on August 25-26, 2026, which the company said did not constitute formal FDA feedback, concurrence or authorization.

Key points

  • Q2 2026 cancer testing revenue up 47% year over year, per the company's sales update
  • 29 orders from new accounts; Maryland Firefighter Cancer Screening Program up more than 200% over 2025
  • Two in-person FDA discussions held August 25-26, 2026; company says no formal FDA feedback or authorization was given
  • Presentation used in the investor webinar held September 2, 2026 (Exhibit 99.1)

The filing

Company20/20 Biolabs, Inc. (AIDX)
Form8-K, current report
Filed with the SECSep 2, 2026, 4:32 PM ET
Accession number0001213900-26-096743

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.